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Controversies in the timing of chest radiotherapy
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Since the metaanalysis conducted by Pignon et al, chest radiotherapy 
is now a classical component in the treatment of limited small cell lung 
cancer. The next question is to deﬁne the optimal way of combining 
drugs and radiation including the drugs, the sequence and the 
characteristics of the radiation treatment (doses, volumes, fractionation 
and timing). So, the issue of timing is only one variable amongst 
different possibilities. This issue have been addressed by a series of 
randomised trials and metaanalysis. 
Six randomised trials have addressed the question of the timing: 5 
have used a concurrent chemo radiotherapy schedule while one used 
a sequential approach (Work). Trials are using a cisplatine based 
chemotherapy and a continuous irradiation (a split-course schedule was 
only used in the Work trial). The timing of chest RT varies from 42 to 
169 days for the late group and during the ﬁrst cycle of chemotherapy 
for the early group. Three trials are in favour of an early administra-
tion (Murray, Skarios, Jeremic) while 3 are in favour of a late chest RT 
(Spiro, Work, Perry). Except for Murray and Works trials, the late chest 
irradiation was delivered within 64 days and certainly not at the end of 
the chemotherapy programme. It is interesting to compare the results 
of Spiro and Murray trial with a very similar design but leading to dif-
ferent results: the Spiro trial favours the late chest RT while the Murray 
is in favour of an early administration. There are some differences in 
the treatment design: the timing of chest radiotherapy was respectively 
on day 22 and 105 for Murray trial and on day 1 and 64 for the Spiro 
trial The radiation schedule was also slightly different: 40 Gy in 15 
fractions over 3 weeks for Murray and 50 Gy in 25 fractions over 5 
weeks for Spiro. Nevertheless, chemotherapy compliance was certainly 
the main difference between the two trials: in Spiro trial, the six cycles 
of chemotherapy were given to 69% of the patients in the early RT vs. 
80% for the late group while in the Murray trial there was no major 
difference between the two arms with a chemotherapy compliance over 
80%. In general, the compliance to chemotherapy was reduced in most 
trials in case of the early chest RT (Skarios, Work, Perry). 
Different metaanalysis have been conducted including some of those 
trials and other trials not especially design to study the timing but were 
a difference in timing was observed between the two arms (An alternat-
ing schedule vs. a sequential for the Gregor trial and an early concur-
rent approach vs. a sequential for the Japanese trial). The deﬁnition of 
early varies from one metaanalysis to another (from within one month 
or before the 3 cycles of chemotherapy). 
In those metaanalysis, there was a trend in favor of an early radiothera-
py when the non-platinum chemotherapy trials were excluded. In Fried 
metaanalysis including 7 trials, an early RT means an RT delivered 
within 9 weeks or before the 3 cycles of chemotherapy. A beneﬁt in 
favor of an early chest RT was seen only for platinum based chemo-
therapy and for hyper fractionated radiation schedule. In the Cochrane 
analysis, only a trend was observed in favor of a chest RT delivered 
within 30 days after the start of chemotherapy after excluding the Perry 
trial. If 5-year data are taking into account, then thoracic radiation de-
livered within 30 days after the start of radiation increases the survival 
from 13.8 to 20.2% but at the expense of more acute toxicity, esophagi-
tis and leucopenia. 
Furthermore, reviewing the data available from randomized trial, De 
Ruysscher and Vansteenkiste introduced the SER concept: this is the 
time elapsed between the start of any therapy and the end of the radia-
tion: in an analysis including 5 trials (Takada, Jeremic, Murray, Work 
and Turrisi), a short SER time let to a clear survival beneﬁt This con-
cept is based on the assumptions that the ﬁrst cytotoxic insult may trig-
gers an accelerated tumor repopulation and a more aggressive treatment 
is an important issue. It is interesting to notice that in Murray trial the 
radiation was an accelerated schedule 45 Gy in 3 weeks and in Turrisi 
trial the accelerated schedule (45 Gy in 3 weeks with 2 fractions a day) 
let to a clear survival advantage over the classical 45 Gy in 5 weeks.
In conclusion, there is certainly not a clear answer but the data may 
suggest a small advantage for a concurrent chemo radiotherapy ap-
proach and an early administration of chest radiotherapy. This implies 
to have an adequate patient selection including the extent of the tumor 
and the patient co morbidities, to avoid an excessive toxicity and to 
ensure a good compliance to the subsequent chemotherapy cycles. This 
raises another question: is the classical deﬁnition of limited disease the 
good one to help us to select the patient for an aggressive approach. 
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Controversy in small cell lung cancer : targeted therapy
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For three decades, trials of new chemotherapy regimens for small cell 
lung cancer (SCLC) have failed to substantially improve clinical out-
comes. The promise of targeted therapy has yet to be realised for SCLC 
but there is cautious optimism that there will soon be a breakthrough 
for this disease. 
Angiogenesis Inhibitors : To date the majority of agents evaluated 
in SCLC have been inhibitors of angiogenesis. Trials of interferons 
conducted during the early 1990’s were halted due to lack of signiﬁ-
cant beneﬁt and toxicities that limited administration [1-4]. Trials of 
matrix metalloproteinase inhibitors also failed, and proved toxic due to 
musculoskeletal toxicity [5,6]. The ﬁrst evidence that inhibition of an-
giogenesis may be a viable therapeutic strategy comes from the results 
of a randomised, phase III, placebo-controlled trial of maintenance 
thalidomide in patients with previously untreated extensive stage SCLC 
conducted by the French Intergroup [7]. The thalidomide treated group 
had a median survival of 11.7 months versus 8.7 months for the pla-
cebo group (HR: 0.48 [95% CI: 0.24-0.93]; p = 0.03). However toxic-
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ity, principally neuropathy and constipation led to withdrawal from the 
study in just over half the patients who received thalidomide. In a phase 
III trial conducted by the London Lung Cancer Group a lower dose 
(100-200mg daily) of thalidomide has been evaluated in combination 
with etoposide and cisplatin but results are not yet available. Due to the 
toxicities observed with thalidomide and the success of bevacizumab 
(Avastin, Genentech, San Francisco, CA, USA), a humanized mono-
clonal antibody directed against the vascular endothelial cell growth 
factor (VEGF) in non-small cell lung and colorectal cancer, results 
from trials of this agent in SCLC are awaited with interest. Bevaci-
zumab is generally well-tolerated although associated with increased 
risk of fatal haemorrhage, hypertension and thromboembolic events 
[8]. Vandetanib (Zactima, Astra-Zeneca, Macclesﬁeld, UK), a small 
molecule oral inhibitor of VEGF receptor-2 tyrosine kinase, and to a 
lesser extent, epidermal growth factor receptor (EGFR) tyrosine kinase, 
is also well tolerated. The main side effects of vandetanib are thrombo-
cytopenia, diarrhoea, rash and asymptomatic QTc prolongation [9]. A 
number of studies in SCLC are ongoing with these agents [10], some 
of which have completed recruitment. The National Cancer Institute 
of Canada - Clinical Trials Group have recently completed recruitment 
to a randomized phase II trial of vandetanib as maintenance chemo-
therapy in patients with SCLC with a response to ﬁrst line treatment. A 
Cancer and Leukemia Group B (CALGB) study of cisplatin, irinote-
can and bevacizumab in extensive stage SCLC, and a Sarah Cannon 
Research Institute trial evaluating carboplatin,irinotecan and concurrent 
radiotherapy followed by bevacizumab in limited stage SCLC have 
also completed recruitment. Other anti-angiogenic agents that are being 
evaluated include sorafenib (Nexafar, Bayer Pharmaceuticals, West 
Haven, CT, USA; Onyx Pharmaceuticals, Richmond, CA, USA), that 
is a multiple kinase inhibitor of Raf kinase, VEGFR-2, VEGFR-3, and 
platelet-derived growth factor receptor beta and AZD2171 (AstraZen-
eca, Macclesﬁeld, UK), an inhibitor of VEGFR-1, VEGFR-2, VEGFR-
3, c-kit, platelet derived growth factor alpha and beta [10].
Growth and proliferation pathway inhibitors : Several studies identify 
c-kit tyrosine kinase signalling as a dominant pathway for growth that 
is upregulated in SCLC [11]. However, the clinical trials of imatinib 
(Gleevec, Glivec, Novartis, Basel, Switzerland; East Hanover, NJ, 
USA), a small molecule inhibitor of the c-kit tyrosine kinase, proved 
particularly disappointing. Negative results were ﬁrst attributed to in-
clusion of patients with tumours that did not express the c-kit receptor 
[12], but imatinib subsequently failed in trials that selected for patients 
with c-kit positive tumours [13-15]. Also, a combination study of 
imatinib with irinotecan demonstrated higher than anticipated neu-
tropenia, diarrhoea, and thrombosis likely due to decreased clearance 
of irinotecan in the presence of imatinib [16]. The potent efﬁcacy of 
imatinib in patients with gastrointestinal stromal tumours is attributed 
to the presence of activating mutations in the c-kit tyrosine kinase 
domain. The rare occurrence of c-kit mutation in SCLC may account 
for the failure of imatinib in this disease. The EGFR inhibitor, geﬁtinib 
(Iressa, AstraZeneca, Macclesﬁeld, UK), also failed in SCLC [17] but 
this is less surprising because over-expression of EGFR is infrequent in 
SCLC compared to non-small cell lung cancer. Temsirolimus (Wyeth 
Pharmaceuticals, Collegeville, PA, USA) inhibits the mammalian target 
of rapamycin (mTOR), a downstream mediator in the phosphoinositide 
3-kinase (PI3K)/AKT signaling pathway, leading to cell cycle arrest. 
A randomized phase II trial of temsirolimus maintenance conducted 
in patients with extensive stage SCLC was not conclusive for further 
evaluation [18]. Another strategy to inhibit growth signal transduction 
cascades in tumours is farnesyl transferase inhibition but this does not 
appear to be a feasible approach for SCLC [19].
Apoptosis promoters : Defective apoptosis underpins cancer cell 
survival and treatment resistance . The Bcl-2 family proteins are central 
regulators of apoptosis and Bcl-2 is overexpressed in 90% of SCLC 
[20]. Oblimersen (Genasense, Genta, Berkeley Heights, NJ, USA), 
an antisense oligonucleotide, is the ﬁrst bcl-2 inhibitor to be tested in 
SCLC. In a phase I study, administration of oblimersen with carbopla-
tin and etoposide was well tolerated with a response rate of 86% and 
time to disease progression of 5.9 months in patients with extensive 
stage disease [21]. Results from phase II evaluation are currently 
awaited. Several small molecule inhibitors of Bcl-2 family proteins are 
in preclinical development and will soon enter clinical trial. Notably, 
ABT-737 (Abbott Laboratories San Diego, California, USA) inhibits 
the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, and has demon-
strated unprecedented single agent activity in SCLC xenografts [22]. 
Other pro-apoptotic strategies include aplidine (Pharma Mar, Madrid 
Spain; Cambridge, USA), a novel marine cyclodepsipeptide that 
also has antiangiogenic properties. Aplidine is noted to cause muscle 
toxicity [23] and the results of phase II testing in SCLC are due to be 
reported soon. The 3-hydroxy-3methylglutaryl CoA reductase inhibitor 
simvastatin suppresses growth, induces apoptosis and enhances sensi-
tivity to etoposide in preclinical studies of SCLC [24]. A phase III trial 
to evaluate the concept that statins combined with chemotherapy will 
improve on chemotherapy alone has recently opened in Great Britain 
and a phase II study is also open in South Korea [10]. Apoptosis has 
also been correlated with proteasome activity. Bortezomib is a protea-
some inhibitor that has been approved for use in multiple myeloma. In 
SCLC cell lines bortezomib reduces Bcl-2 levels and induces apopto-
sis[25] but it is not active as a single agent in patients with extensive 
stage SCLC[26] and results from combination studies are awaited. 
Perspectives and Future challenges : The development of targeted 
therapy for SCLC is proving frustrating. Although various targeted 
therapies have been evaluated, the majority of studies have been 
conducted in ‘untargeted’ populations[27]. Yet, strong preclinical data 
to pursue c-kit inhibition with imatinib did not translate to the clinic 
even when patients were selected for tumoural expression of c-kit. One 
caveat to using SCLC tumour for patient selection is the propensity 
for this disease to be exquisitively chemo / radiosensitive at presenta-
tion but substantially more resistant to treatment at relapse. Targets 
identiﬁed in chemonaive tumours may be irrelevant for previously 
treated tumours. Thus, greater understanding of mechanisms governing 
treatment resistance may be required to shape the future development 
of targeted therapy and aid in selection of the most appropriate agents 
to prioritise for trials in this disease.
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The role of irinotecan in the treatment of small cell lung cancer
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Since the 1960’s, small cell lung cancer (SCLC) has been recognized as 
a distinct subtype of lung cancer with a unique sensitivity to chemo-
therapy (1). Multiple therapeutic agents and strategies tested over the 
last 3 decades result in a 1 year survival rate of 30-40% for patients 
with extensive stage disease (ED). Unfortunately, unlike other chemo-
therapy-sensitive cancers such as lymphoma and germ cell tumors, sig-
niﬁcant advances in the treatment of ED SCLC have stalled. Testing of 
“newer” chemotherapy agents such as epirubicin, ifosfamide, vinorel-
bine, the taxanes, and gemcitabine, have failed to improve survival 
compared with the older chemotherapy agents, cisplatin and etoposide 
(PE). In the U.S. PE for 4 cycles has been standard ﬁrst line therapy 
based upon the results of randomized trials which indicated that other 
regimens were not superior, but rather resulted in more inconvenience 
and toxicity (2).
Camptothecin is a plant alkaloid present in the Asian tree Camptotheca 
acuminata. Camptothecin was recognized as a potential anti-cancer 
drug based upon a screening program conducted by the U.S. National 
Cancer Institute in the 1960’s (3). During replication, DNA unwinds 
so that single strands serve as a template for synthesis of new DNA 
strands. Topoisomerase 1 plays a critical role in the cleavage of single 
DNA strands, necessary to allow the broken strand of DNA to rotate 
around the intact strand during DNA replication. Camptothecins target 
topoisomerase 1 by stabilizing the cleavable complex between topoi-
somerase 1 and DNA (4). Irinotecan, a water-soluble semi synthetic 
derivative of camptothecin, entered clinical trials in the 1980’s. Irino-
tecan is a prodrug of the metabolite, SN38, which has 2-3 logs greater 
activity than irinotecan. Importantly, SN-38 is cleared by uridine 
diphosphate glycosyltransferase 1 family polypeptide A1 (UGT1A1), 
an enzyme important for biliary glucuronidation. Patients with certain 
polymorphisms in the promoter region of UGT1A1 are at higher risk 
for diarrhea and neutropenia (5).
In 2002, Noda et al reported the results of a phase III trial from the 
Japanese Cooperative Oncology Group (JCOG) that compared treat-
ment with cisplatin plus either irinotecan or etoposide in 154 patients 
with ED SCLC (6). Median and 1 year survival was signiﬁcant im-
proved in the patients receiving the irinotecan-based regimen compared 
with PE (12.8 months vs. 9.4 months, 58.4% vs. 37.7%, respectively). 
Patients on the PE arm experienced more neutropenia and thrombocy-
topenia, while patients on the IP arm experienced more diarrhea. The 
study was discontinued early based upon the recommendation of a data 
monitoring committee. A phase III trial conducted in the U.S., Canada, 
and Australia, utilizing a different dose and schedule of irinotecan and 
cisplatin failed to conﬁrm a survival advantage for the IP arm over 
the EP arm (7). Despite a change in the dose and schedule of IP, rates 
of gastrointestinal toxicity, namely vomiting and diarrhea were not 
substantially reduced, although dose intensity was improved compared 
with the IP regimen utilized in the JCOG trial. While there are several 
plausible reasons to explain the disparate results from the two trials, 
known pharmacogenomic differences between North American and 
Japanese populations likely played a role in determining both toxicity 
and efﬁcacy proﬁles of IP. Speciﬁcally, polymorphisms in UGT1A1 are 
observed between patient populations. Low rates of Gilbert’s syndrome 
(decreased level of gene transcription of UGT1A1) are recognized 
in Asian populations (8). In one study in non-small cell lung cancer, 
patients with Gilbert’s syndrome experienced more toxicity and worse 
survival with IP (9). Differences in toxicity and efﬁcacy proﬁles 
amongst North American and Japanese patients utilizing the same 
drugs have been reported (10). Similarly, UGT1A1*6 and UGT1A9*22 
genotypes have recently been reported to be associated with irnotecan-
related toxicity, response, and survival in Korean patients (11).
While PE remains standard in the U.S. for now, IP is an equally ef-
fective alternative regimen against ED SCLC. The substitution of 
carboplatin for cisplatin in the IP regimen has been explored in phase 
II and randomized phase II studies. Progression free survival favored 
